Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up

López-Nava, Gontrand; Sharaiha, Reem Z.; Vargas, Eric J.; Bazerbachi, Fateh; Manoel, Galvao Neto; Bautista-Castaño, Inmaculada; Acosta, Andrés; Topazian, Mark D.; Mundi, Manpreet S.; Kumta, Nikhil A.; Kahaleh, Michel; Herr, A.M.; Shukla, Alpana; Aronne, Louis J.; Gostout, Christopher J.; Dayyeh, Barham K. Abu

doi:10.1007/s11695-017-2693-7

Cited by 198 publications

(116 citation statements)

References 28 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to prior smaller‐scale prospective studies . Long‐term effectiveness of ESG was confirmed at 24 months with a TBWL of 18.6% …”

Section: Gastric Remodeling Proceduressupporting

confidence: 89%

“…Unlike POSE, ESG does not include suturing the fundus because it is quite difficult to perform in the retroflexed position with this device. Since the first technical feasibility study conducted on four patients by Abu Dayyeh et al was published, many subsequent studies have demonstrated the safety and efficacy of ESG in both weight loss and improvement in metabolic and physiologic parameters in patients with BMI between 30.0 and 40.0 kg/m 2 . In the largest multicenter retrospective study conducted to date (n = 248), TBWL with ESG was reported to be 15.2% at 6 months .…”

Section: Gastric Remodeling Proceduresmentioning

confidence: 99%

“…Serious adverse events with ESG are rare (<2%) and include the formation of perigastric inflammatory fluid collections, extragastric hemorrhage, pulmonary embolism after the procedure, perigastric leak, pneumoperitoneum, and pneumothorax. All patients with serious adverse events made full recoveries without invasive surgical intervention . Mild adverse events were not routinely recorded, although one study reported that 38.4% of patients experienced self‐limited nausea and mild abdominal pain lasting <48 hours after the procedure …”

Section: Gastric Remodeling Proceduresmentioning

confidence: 99%

“…Since the first technical feasibility study conducted on four patients by Abu Dayyeh et al was published, 34 many subsequent studies have demonstrated the safety and efficacy of ESG in both weight loss and improvement in metabolic and physiologic parameters in patients with BMI between 30.0 and 40.0 kg/m 2 . [34][35][36][37][38][39][40] In the largest multicenter retrospective study conducted to date (n = 248), TBWL with ESG was reported to be 15.2% at 6 months. 38 These results are similar to prior smaller-scale prospective studies.…”

Section: Non-space-occupying Therapiesmentioning

confidence: 99%

“…[34][35][36][37][38][39][40] In the largest multicenter retrospective study conducted to date (n = 248), TBWL with ESG was reported to be 15.2% at 6 months. 38 These results are similar to prior smaller-scale prospective studies. 36,37,40 Long-term effectiveness of ESG was confirmed at 24 months with a TBWL of 18.6%.…”

Section: Non-space-occupying Therapiesmentioning

confidence: 99%

See 4 more Smart Citations

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Chablaney

Kumta

2019

Journal of Diabetes

View full text Add to dashboard Cite

Endoscopic bariatric and metabolic therapies (EBMTs) have sparked significant interest as minimally invasive therapeutic options for weight loss. Although bariatric surgery remains an effective option for sustained weight loss and improvement in the metabolic syndrome, access and utilization are limited. Various EBMTs have been designed to emulate the physiologic effects of established surgical interventions, including space‐occupying and non‐space‐occupying gastric therapies, gastric remodeling procedures, and small bowel therapies. This review discusses the safety and efficacy of available US Food and Drug Administration‐approved minimally invasive endoscopic bariatric interventions, as well as those currently under investigation. In addition, the role of endoscopic revision after failed surgical intervention is discussed.

show abstract

“…These results are similar to prior smaller‐scale prospective studies . Long‐term effectiveness of ESG was confirmed at 24 months with a TBWL of 18.6% …”

Section: Gastric Remodeling Proceduressupporting

confidence: 89%

Section: Gastric Remodeling Proceduresmentioning

confidence: 99%

Section: Gastric Remodeling Proceduresmentioning

confidence: 99%

Section: Non-space-occupying Therapiesmentioning

confidence: 99%

Section: Non-space-occupying Therapiesmentioning

confidence: 99%

See 3 more Smart Citations

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Chablaney

Kumta

2019

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

Haseeb,

Chhatwal,

Xiao

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceObesity is a disease with a large socioeconomic burden. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoscopic bariatric procedure with wide global adoption. More recently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (eg, semaglutide), have attracted increased attention due to their efficacy. However, their cost-effectiveness over an extended period compared with ESG is a critical gap that needs to be better explored for informed health care decision-making.ObjectiveTo assess the cost-effectiveness of semaglutide compared with ESG over 5 years for individuals with class II obesity.Design, Setting, and ParticipantsThis economic evaluation study, conducted from September 1, 2022, to May 31, 2023, used a Markov cohort model to compare ESG and semaglutide, with a no-treatment baseline strategy. The study comprised adult patients in the US health care system with class II obesity (body mass index [BMI] of 35-39.9). The base case was a 45-year-old patient with class II obesity (BMI of 37). Patients undergoing ESG were subjected to risks of perioperative mortality and adverse events with resultant costs and decrement in quality of life.InterventionsStrategies included treatment with semaglutide and ESG.Main Outcomes and MeasuresCosts (2022 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) with a willingness-to-pay threshold of $100 000/QALY. A 5-year time horizon with a cycle length of 1 month with a 3% discount rate was used. Probabilities, costs, and quality-of-life estimates of the model were derived from published literature. One-way, 2-way, and probabilistic sensitivity analyses were also performed.ResultsThe model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of –$595 532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33 583 relative to semaglutide. The results remained robust on 1-way and probabilistic sensitivity analyses. Endoscopic sleeve gastroplasty sustained greater weight loss over 5 years vs semaglutide (BMI of 31.7 vs 33.0). To achieve nondominance, the annual price of semaglutide, currently $13 618, would need to be $3591.Conclusions and RelevanceThis study suggests that ESG is cost saving compared with semaglutide in the treatment of class II obesity. On price threshold analyses, a 3-fold decrease in the price of semaglutide is needed to achieve nondominance.

show abstract

Training in Bariatric Endoscopy

Jirapinyo¹,

Thompson²

2022

Successful Training in Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up

Abstract: ESG effectively induces weight loss up to 24 months in moderately obese patients. Failure to achieve adequate weight loss can be predicted early, and patients should be offered adjunctive therapies to augment it.

Cited by 198 publications

References 28 publications

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

Training in Bariatric Endoscopy

Contact Info

Product

Resources

About